Ajanta Pharma Limited (IN:AJANTPHARM)
:AJANTPHARM
Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹2920.85
-₹25.05(-0.84%)
At close: 4:00 PM EST
₹2920.85
-₹25.05(-0.84%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,314.80
Previous CloseN/A
Volume47.67K
Average Volume (3M)2.10K
Market Cap
₹383.90B
Enterprise Value₹367.48B
Total Cash (Recent Filing)₹9.40B
Total Debt (Recent Filing)₹2.46B
Price to Earnings (P/E)36.4
Beta0.33
Next Earnings
Jul 23, 2026EPS Estimate
25.1Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)77.91
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)99.71
Revenue Forecast (FY)₹62.26B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and consistently strong ROE provide durable financial flexibility. This conservatism lets the company fund product launches, capex or M&A without immediate refinancing, absorb industry shocks, and maintain investment-grade-like optionality, supporting multi‑quarter resilience.
Consistent Revenue GrowthSustained top-line growth indicates steady demand for branded generics and effective commercial execution. Combined with multi-geography sales channels and new product introductions, this trend supports predictable medium-term cash flows and economies of scale across manufacturing and marketing.
Strong Historical Margins And In-house ManufacturingHealthy, consistent margins reflect pricing power, tight cost control and value capture from in‑house formulation manufacturing. These structural advantages support sustainable cash generation and reinvestment capacity, underpinning long‑term profitability even as the company scales.
Bears Say
Weakened Cash ConversionVolatile and deteriorating cash conversion reduces predictability of internally generated funds for capex, dividends or debt repayment. If working-capital swings persist, the company may need external financing for growth or to sustain payouts, increasing financial risk over the next several quarters.
Margin Compression In FY2026A pronounced decline in gross and operating margins suggests pressure from input costs, pricing or adverse product mix. If structural rather than temporary, this erodes pricing power and return on invested capital, forcing either cost restructuring or slower earnings growth going forward.
Uptick In DebtRising debt, even from a low base, reduces financial headroom if cash conversion is weakening. Increased leverage heightens sensitivity to interest costs and limits flexibility for opportunistic investments, making the capital structure more vulnerable if earnings or cash flows deteriorate.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3314.80 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹383.90B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Jul 23, 2026 which is in 42 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on May 05, 2026. The company reported ₹21.3 earnings per share for the quarter, beating the consensus estimate of ₹20.13 by ₹1.17.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹28 which represents an annual dividend yield of 1.04%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 25.1.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,935,620 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹21.3 in its last earnings report, beating expectations of ₹20.13. Following the earnings report the stock price went down -0.112%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Gland Pharma Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Laurus Labs Ltd.
―